

# Praveen Thokala

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9154984/publications.pdf>

Version: 2024-02-01

77  
papers

2,831  
citations

236925

25  
h-index

182427

51  
g-index

82  
all docs

82  
docs citations

82  
times ranked

4050  
citing authors

#	ARTICLE	IF	CITATIONS
1	Economic, clinical and social impact of simple limbal epithelial transplantation for limbal stem cell deficiency. <i>British Journal of Ophthalmology</i> , 2022, 106, 923-928.	3.9	17
2	Healthcare professionals' views on factors influencing shared decision-making in primary health care centres in Saudi Arabia: A qualitative study. <i>Journal of Evaluation in Clinical Practice</i> , 2022, 28, 235-246.	1.8	3
3	The relationship between chronic kidney disease-associated pruritus and health-related quality of life: a systematic review. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 484-499.	2.9	7
4	Topic selection process in health technology assessment agencies around the world: a systematic review. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e19.	0.5	2
5	The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 385-394.	4.5	11
6	Priority setting of vaccine introduction in Bangladesh: a multicriteria decision analysis study. <i>BMJ Open</i> , 2022, 12, e054219.	1.9	4
7	ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients. <i>Applied Health Economics and Health Policy</i> , 2022, , .	2.1	0
8	Cost-effectiveness of out-of-hospital continuous positive airway pressure for acute respiratory failure: decision analytic modelling using data from a feasibility trial. <i>BMC Emergency Medicine</i> , 2021, 21, 13.	1.9	0
9	Prehospital continuous positive airway pressure for acute respiratory failure: the ACUTE feasibility RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-92.	2.8	4
10	Views of stakeholders on factors influencing shared decision-making in the Eastern Mediterranean Region: a systematic review. <i>Eastern Mediterranean Health Journal</i> , 2021, 27, 300-311.	0.8	4
11	Configuration of vascular services: a multiple methods research programme. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-150.	1.0	1
12	The CAPACITI Decision-Support Tool for National Immunization Programs. <i>Value in Health</i> , 2021, 24, 1150-1157.	0.3	9
13	Clarifying Values: An Updated and Expanded Systematic Review and Meta-Analysis. <i>Medical Decision Making</i> , 2021, 41, 801-820.	2.4	43
14	The effectiveness and value of belimumab and voclosporin for lupus nephritis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1495-1499.	0.9	2
15	Study protocol for a randomised clinical trial of a decision aid and values clarification method for parents of a fetus or neonate diagnosed with a life-threatening congenital heart defect. <i>BMJ Open</i> , 2021, 11, e055455.	1.9	4
16	Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review. <i>Pharmacoeconomics</i> , 2020, 38, 269-283.	3.3	18
17	The Impact of Including Costs and Outcomes of Dementia in a Health Economic Model to Evaluate Lifestyle Interventions to Prevent Diabetes and Cardiovascular Disease. <i>Medical Decision Making</i> , 2020, 40, 912-923.	2.4	4
18	What Influences the Implementation of Shared Decision Making: An Umbrella Review. <i>Patient Education and Counseling</i> , 2020, 103, 2400-2407.	2.2	33

#	ARTICLE	IF	CITATIONS
19	Scoping Review: Intergenerational Resource Transfer and Possible Enabling Factors. International Journal of Environmental Research and Public Health, 2020, 17, 7868.	2.6	9
20	Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Effectiveness and Resource Allocation, 2020, 18, 41.	1.5	19
21	Is a definitive trial of prehospital continuous positive airway pressure versus standard oxygen therapy for acute respiratory failure indicated? The ACUTE pilot randomised controlled trial. BMJ Open, 2020, 10, e035915.	1.9	6
22	HTA™d in the USA: A Comparison of ICER in the United States with NICE in England and Wales. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1162-1170.	0.9	6
23	<p>Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach</p>. International Journal of COPD, 2020, Volume 15, 787-797.	2.3	1
24	Establishing a Porcine Ex Vivo Cornea Model for Studying Drug Treatments against Bacterial Keratitis. Journal of Visualized Experiments, 2020, , .	0.3	7
25	Developing Markov Models From Real-World Data: A Case Study of Heart Failure Modeling Using Administrative Data. Value in Health, 2020, 23, 743-750.	0.3	9
26	Qualitative exploration of patient flow in a Caribbean emergency department. BMJ Open, 2020, 10, e041422.	1.9	2
27	Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. Value in Health, 2019, 22, 1283-1288.	0.3	97
28	A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement. Medical Decision Making, 2019, 39, 899-909.	2.4	28
29	Modeling the Economic Impact of Interventions for Older Populations with Multimorbidity: A Method of Linking Multiple Single-Disease Models. Medical Decision Making, 2019, 39, 842-856.	2.4	1
30	Direct medical costs in the preceding, event and subsequent years of a first severe hypoglycaemia episode requiring hospitalization: A population-based cohort study. Diabetes, Obesity and Metabolism, 2019, 21, 1330-1339.	4.4	6
31	A role for MCDA to navigate the trade-offs in the National Institute for Health and Care Excellence™s public health recommendations. Operations Research for Health Care, 2019, 23, 100179.	1.2	6
32	The Effectiveness and Value of Treatments for Spinal Muscular Atrophy. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1300-1306.	0.9	9
33	Direct medical costs of diabetes mellitus in the year of mortality and year preceding the year of mortality. Diabetes, Obesity and Metabolism, 2018, 20, 1470-1478.	4.4	14
34	Cost-Effectiveness Thresholds: the Past, the Present and the Future. Pharmacoeconomics, 2018, 36, 509-522.	3.3	124
35	Stakeholder involvement in Multi-Criteria Decision Analysis. Cost Effectiveness and Resource Allocation, 2018, 16, 0.	1.5	8
36	Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings. Cost Effectiveness and Resource Allocation, 2018, 16, 43.	1.5	24

#	ARTICLE	IF	CITATIONS
37	Sex differences in national rates of repair of emergency abdominal aortic aneurysm. <i>British Journal of Surgery</i> , 2018, 106, 82-89.	0.3	23
38	Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force. <i>Value in Health</i> , 2018, 21, 1019-1028.	0.3	36
39	Cost-benefit analysis of introducing next-generation sequencing (metagenomic) pathogen testing in the setting of pyrexia of unknown origin. <i>PLoS ONE</i> , 2018, 13, e0194648.	2.5	13
40	Interventions to improve patient flow in emergency departments: an umbrella review. <i>Emergency Medicine Journal</i> , 2018, 35, 626-637.	1.0	60
41	The ACUTE (Ambulance CPAP: Use, Treatment effect and economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure. <i>Pilot and Feasibility Studies</i> , 2018, 4, 86.	1.2	9
42	The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective. <i>European Journal of Heart Failure</i> , 2017, 19, 661-669.	7.1	47
43	Incorporating Preferences and Priorities into MCDA: Selecting an Appropriate Scoring and Weighting Technique. , 2017, , 47-66.		4
44	Constrained Optimization Methods in Health Services Research—An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. <i>Value in Health</i> , 2017, 20, 310-319.	0.3	79
45	Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment. <i>Pharmacoeconomics</i> , 2017, 35, 989-1006.	3.3	18
46	Cost effectiveness of using cognitive screening tests for detecting dementia and mild cognitive impairment in primary care. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1392-1400.	2.7	56
47	MCDA for Resource Allocation at a Local Level: An Application in the UK. , 2017, , 175-198.		1
48	Economic impact of Tegaderm chlorhexidine gluconate (CHG) dressing in critically ill patients. <i>Journal of Infection Prevention</i> , 2016, 17, 216-223.	0.9	11
49	Using MCDA to generate and interpret evidence to inform local government investment in public health. <i>EURO Journal on Decision Processes</i> , 2016, 4, 161-181.	2.7	6
50	Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. <i>Value in Health</i> , 2016, 19, 1-13.	0.3	437
51	Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective. <i>Pharmacoeconomics</i> , 2016, 34, 741-750.	3.3	11
52	Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. <i>Value in Health</i> , 2016, 19, 125-137.	0.3	320
53	Resource Modelling: The Missing Piece of the HTA Jigsaw?. <i>Pharmacoeconomics</i> , 2015, 33, 193-203.	3.3	14
54	The return of public health to local government in England: changing the parameters of the public health prioritization debate?. <i>Public Health</i> , 2015, 129, 1194-1203.	2.9	35

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of Out-of-Hospital Continuous Positive Airway Pressure for Acute Respiratory Failure. <i>Annals of Emergency Medicine</i> , 2015, 65, 556-563.e6.	0.6	7
56	The economics of cardiac biomarker testing in suspected myocardial infarction. <i>Clinical Biochemistry</i> , 2015, 48, 213-217.	1.9	9
57	Incorporating Psychological Predictors of Treatment Response into Health Economic Simulation Models. <i>Medical Decision Making</i> , 2015, 35, 872-887.	2.4	1
58	Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-102.	2.8	43
59	High-sensitivity troponin assays for the early rule-out or diagnosis of acute myocardial infarction in people with acute chest pain: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2015, 19, 1-234.	2.8	39
60	Prioritising public health guidance topics in the National Institute for Health and Care Excellence using the Analytic Hierarchy Process. <i>Public Health</i> , 2014, 128, 896-903.	2.9	29
61	Assessing the cost-effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy Model. <i>Diabetic Medicine</i> , 2014, 31, 477-486.	2.3	27
62	Multi Criteria Decision Analysis Methods In Health Care: Current Status, Good Practice And Future Recommendations. <i>Value in Health</i> , 2014, 17, A34.	0.3	3
63	Improving management of type 1 diabetes in the UK: the Dose Adjustment For Normal Eating (DAFNE) programme as a research test-bed. A mixed-method analysis of the barriers to and facilitators of successful diabetes self-management, a health economic analysis, a cluster randomised controlled trial of different models of delivery of an educational intervention and the potential of insulin pumps and additional educator input to improve outcomes. <i>Programme Grants for Applied Research</i> , 2014, 2, 1-188.	1.0	28
64	Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. <i>BMJ Open</i> , 2013, 3, e003250.	1.9	41
65	Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. <i>Age and Ageing</i> , 2013, 42, 14-20.	1.6	82
66	The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model. <i>Diabetic Medicine</i> , 2013, 30, 1236-1244.	2.3	37
67	Systematic review, meta-analysis and economic modelling of diagnostic strategies for suspected acute coronary syndrome. <i>Health Technology Assessment</i> , 2013, 17, v-vi, 1-188.	2.8	104
68	Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE). <i>Health Technology Assessment</i> , 2013, 17, v-vi, 1-122.	2.8	36
69	Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2013, 17, 1-207, v-vi.	2.8	100
70	The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. <i>Health Technology Assessment</i> , 2012, 16, 1-470.	2.8	213
71	Cost-effectiveness of presentation versus delayed troponin testing for acute myocardial infarction. <i>Heart</i> , 2012, 98, 1498-1503.	2.9	40
72	Multiple Criteria Decision Analysis for Health Technology Assessment. <i>Value in Health</i> , 2012, 15, 1172-1181.	0.3	231

#	ARTICLE	IF	CITATIONS
73	Framework for Aircraft Cost Optimization Using Multidisciplinary Analysis. Journal of Aircraft, 2012, 49, 367-374.	2.4	7
74	Life cycle cost modelling as an aircraft design support tool. Proceedings of the Institution of Mechanical Engineers, Part G: Journal of Aerospace Engineering, 2010, 224, 477-488.	1.3	12
75	Variable-complexity optimization applied to airfoil design. Engineering Optimization, 2007, 39, 271-286.	2.6	16
76	Simulation-Based Life Cycle Cost Modelling as a Decision Support Tool. , 2007, , .		1
77	A review of public health economic modelling in the National Institute for Health and Care Excellence (NICE). HRB Open Research, 0, 3, 30.	0.6	0